Denali Therapeutics (DNLI) Change in Accured Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Change in Accured Expenses data on file, last reported at -$22.4 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$22.4 million, down 131.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$12.2 million (down 39.79% YoY), and the FY2025 annual result was $465000.0, down 85.68% from the prior year.
• Change in Accured Expenses slipped to -$22.4 million in Q1 2026 per DNLI's latest filing, from $12.7 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $24.6 million in Q3 2024 and troughed at -$32.2 million in Q2 2023.
• A 5-year average of -$300941.2 and a median of $1.9 million in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses sank 649.17% in 2023, then soared 3249.59% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $4.0 million in 2022, then soared by 255.43% to $14.3 million in 2023, then sank by 119.86% to -$2.8 million in 2024, then jumped by 547.82% to $12.7 million in 2025, then plunged by 275.96% to -$22.4 million in 2026.
• Business Quant data shows DNLI's Change in Accured Expenses at -$22.4 million in Q1 2026, $12.7 million in Q4 2025, and $1.9 million in Q3 2025.